COVID-19 | BioTuesdays

Developments

Eiger doses first COVID-19 patients with peginterferon lambda

Eiger BioPharmaceuticals (NASDAQ:EIGR) dosed the first patients in its Phase 2 study of peginterferon lambda for the treatment of mild COVID-19. The study will enroll some 120 patients who will receive either a single...

April 30, 2020

Developments

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

Capricor Therapeutics (NASDAQ:CAPR) reported that all six critical COVID-19 patients who were treated with CAP-1002, an allogeneic cardiac cell therapy, have survived. The six COVID-19 patients, who were admitted to...

April 29, 2020

Markets

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

H.C. Wainwright more than doubled the price target for Arcturus Therapeutics (NASDAQ:ARCT) to $62 from $26, citing impressive preclinical results from its COVID-19 vaccine candidate. Shares of Arcturus jumped $7.96, to...

April 28, 2020

Features

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device is helping to open a new front in the battle against COVID-19. “Optimal volume management and knowledge of capillary status is key to survivability...

April 28, 2020

Developments

iBio sees 500 million COVID-19 vaccine dose capacity at its FastPharming facility

iBio (NYSE AMERICAN:IBIO) estimates that its FastPharming facility could manufacture some 500 million doses of COVID-19 vaccine annually. “If our own proprietary SARS-CoV-2 virus-like particle (VLP) program, IBIO-200...

April 27, 2020

Developments

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), submitted an IND application to the FDA to conduct a Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is a...

April 24, 2020

Developments

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...

April 24, 2020

Markets

BTIG ups Centogene PT to $23 from $18

BTIG raised its price target for Centogene (NASDAQ:CNTG) to $23 from $18, citing a “solid execution” in its pharma and diagnostics segments in 2019. The stock closed at $18.69 on April 23. Analyst Sung Ji Nam writes...

April 24, 2020

Developments

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Charlotte’s Web (TSX:CWEB; OTC:CWBHF) donated $1-million (US) worth of CBD product to individuals who rely on the company’s products and may be struggling financially as a result of the COVID-19 pandemic. The...

April 21, 2020

Developments

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 2 clinical study evaluating low-dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor is designed to block XPO1, a...

April 20, 2020

Developments

Anixa Biosciences in COVID-19 development pact with OntoChem

Anixa Biosciences (NASDAQ:ANIX) entered a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19. “We believe that newly designed drugs that are purposefully developed...

April 20, 2020

Developments

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) enrolled the first patient in its Phase 3 trial assessing tradipitant for the treatment of neurogenic inflammation of the lung, secondary to COVID-19 infection. The study will enroll...

April 15, 2020

Eiger doses first COVID-19 patients with peginterferon lambda

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

HCW ups Arcturus Therapeutics PT to $62 from $26 on COVID-19 data

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

iBio sees 500 million COVID-19 vaccine dose capacity at its FastPharming facility

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

BTIG ups Centogene PT to $23 from $18

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Anixa Biosciences in COVID-19 development pact with OntoChem

Vanda Pharma enrolls first patient in Phase 3 COVID-19 trial

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter